MX395613B - COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER. - Google Patents
COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER.Info
- Publication number
- MX395613B MX395613B MX2019005104A MX2019005104A MX395613B MX 395613 B MX395613 B MX 395613B MX 2019005104 A MX2019005104 A MX 2019005104A MX 2019005104 A MX2019005104 A MX 2019005104A MX 395613 B MX395613 B MX 395613B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- tumors
- compositions
- zinc
- sup
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201609131YA SG10201609131YA (en) | 2016-11-01 | 2016-11-01 | Zinc-pga compositions and methods for treating cancer |
| PCT/SG2017/050545 WO2018084806A1 (en) | 2016-11-01 | 2017-10-31 | ZINC-γ-PGA COMPOSITIONS AND METHODS FOR TREATING CANCER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019005104A MX2019005104A (es) | 2019-10-30 |
| MX395613B true MX395613B (es) | 2025-03-25 |
Family
ID=60327362
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005104A MX395613B (es) | 2016-11-01 | 2017-10-31 | COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER. |
| MX2022011372A MX2022011372A (es) | 2016-11-01 | 2019-04-30 | Composiciones de zinc-y-pga y metodos para tratar el cancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011372A MX2022011372A (es) | 2016-11-01 | 2019-04-30 | Composiciones de zinc-y-pga y metodos para tratar el cancer. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11944640B2 (enExample) |
| EP (1) | EP3534914B1 (enExample) |
| JP (2) | JP7083835B2 (enExample) |
| KR (1) | KR102616690B1 (enExample) |
| CN (2) | CN108014131B (enExample) |
| AU (2) | AU2017354787B2 (enExample) |
| CA (1) | CA3042383A1 (enExample) |
| MX (2) | MX395613B (enExample) |
| SG (3) | SG10201609131YA (enExample) |
| WO (1) | WO2018084806A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| SG10201708886RA (en) * | 2017-10-30 | 2019-05-30 | Xylonix Ip Holdings Pte Ltd | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER |
| MX2020013883A (es) * | 2018-06-22 | 2021-05-27 | Xylonix Ip Holdings Pte Ltd | Tratamientos oncológicos con agentes de zinc. |
| KR102094182B1 (ko) * | 2018-06-28 | 2020-03-30 | 주식회사 알랙스탠드 | 아연 함유 수용성 폴리글루타믹산 복합체 조성물 |
| EP4308166A1 (en) | 2021-03-18 | 2024-01-24 | Xylonix Pte. Ltd. | Pharmaceutical polymer conjugates |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2897122A (en) | 1956-10-04 | 1959-07-28 | Frosst & Co Charles E | Enteric coated product |
| JP2712583B2 (ja) | 1989-06-28 | 1998-02-16 | 味の素株式会社 | 易吸収性ミネラル含有飲食物 |
| JP3551149B2 (ja) | 1992-03-24 | 2004-08-04 | 味の素株式会社 | 易吸収性ミネラル含有組成物及びそれを含有する飲食品 |
| US5447732A (en) | 1992-11-25 | 1995-09-05 | Ajinomoto Co., Inc. | High-absorption mineral-containing composition and foods |
| EP0605757B1 (en) | 1992-11-25 | 2001-08-16 | Ajinomoto Co., Inc. | Compositions and goods containing minerals and poly-gamma-glutamic acid |
| IL115156A (en) | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| IT1275923B1 (it) | 1995-03-16 | 1997-10-24 | Valpharma Sa | Formulazioni gastroresistenti contenenti zinco |
| US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| JPH11313618A (ja) | 1998-05-06 | 1999-11-16 | Yoshio Inoue | 胃にやさしい家畜用ミネラル（亜鉛）製剤及びその製造法 |
| CA2395191A1 (en) | 1999-12-23 | 2001-06-28 | Tedman Ehlers | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
| US20020061599A1 (en) | 1999-12-30 | 2002-05-23 | Elling Christian E. | Method of identifying ligands of biological target molecules |
| WO2003061598A2 (en) | 2002-01-25 | 2003-07-31 | The University Of Georgia Research Foundation, Inc. | Solenopsin a, b and analogs as novel angiogenesis inhibitors |
| WO2004080210A1 (en) | 2003-03-14 | 2004-09-23 | Boehringer Ingelheim Danmark A/S | Compositions of dietary metals for support of the physiological intestinal development and prevention of diarrhoea |
| KR100498812B1 (ko) | 2003-07-10 | 2005-07-01 | 주식회사 바이오리더스 | 초고분자량의 폴리감마글루탐산을 함유하는 미네랄의 체내흡수 촉진용 조성물 |
| JP4457641B2 (ja) | 2003-11-10 | 2010-04-28 | 味の素株式会社 | ゼラチンカプセル |
| JP5162812B2 (ja) | 2004-07-08 | 2013-03-13 | 大正製薬株式会社 | 亜鉛含有経口投与用組成物 |
| ES2392544T3 (es) | 2005-06-07 | 2012-12-11 | Yale University | Métodos de tratamiento del cáncer y otras enfermedades o estados patológicos usando LFMAU y LDT |
| CA2612979A1 (en) * | 2005-06-10 | 2006-12-21 | Bipar Sciences, Inc. | Parp modulators and treatment of cancer |
| JPWO2007043606A1 (ja) * | 2005-10-12 | 2009-04-16 | 株式会社ジェノラックＢｌ | アニオン性ポリアミノ酸／金属複合体からなる抗糖尿病薬剤 |
| WO2007109290A2 (en) | 2006-03-20 | 2007-09-27 | Pharmacyclics, Inc. | Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer |
| JP2010526159A (ja) | 2007-04-10 | 2010-07-29 | 日東電工株式会社 | 多機能性ポリグルタミン酸塩薬物担体 |
| CA2686604A1 (en) | 2007-05-09 | 2008-11-20 | Salutria Pharmaceuticals Llc | Spiro compounds for treatment of inflammatory disorders |
| EP2155253A2 (en) | 2007-05-09 | 2010-02-24 | Nitto Denko Corporation | Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
| JP2012523413A (ja) | 2009-04-10 | 2012-10-04 | サイプレス ファーマシューティカルズ， インコーポレイテッド | ホスフェート結合性マグネシウム塩およびその使用 |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| CN101716180B (zh) | 2009-11-06 | 2013-04-24 | 广西强寿药业集团有限公司 | 一种组合补充锌、钙药物及其制备方法 |
| US20110117210A1 (en) | 2009-11-17 | 2011-05-19 | Andrey Ugolkov | Therapeutic treatment of human cancers using simple salts of zinc |
| CA2800235C (en) | 2010-03-10 | 2018-10-16 | Lupin Limited | Rifaximin ready-to-use suspension |
| KR101892788B1 (ko) | 2011-09-13 | 2018-08-28 | 파마싸이클릭스 엘엘씨 | 벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도 |
| ES2646927T3 (es) | 2012-11-21 | 2017-12-18 | KBS Research, LLC | Suplementos herbales y métodos de uso de los mismos |
| TWI660748B (zh) | 2013-03-01 | 2019-06-01 | 日商大塚製藥股份有限公司 | 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液 |
| EP2978423A4 (en) | 2013-03-28 | 2016-08-24 | Bbs Nanotechnology Ltd | STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH |
| BR112015024537B1 (pt) | 2013-04-12 | 2022-09-06 | Ned Biosystems, Inc | Uso de (i) ciclofosfamida, (ii) metformina, (iii) curcumina, (iv) melatonina, (v) naltrexona, (vi) ácido alfa lipoico e (vii) genisteína e combinação no tratamento de câncer |
| CN105143242A (zh) | 2013-04-26 | 2015-12-09 | 日东电工株式会社 | 大规模制备聚(谷氨酰基-谷氨酸盐)偶联物的方法 |
| WO2015009699A1 (en) | 2013-07-15 | 2015-01-22 | Ketter Patrick | Methods and compositions to prevent or treat bacterial infections |
| JP2016069303A (ja) | 2014-09-29 | 2016-05-09 | タカラバイオ株式会社 | フコイダンを有効成分とする脱毛抑制用組成物 |
| ES2630106T3 (es) | 2014-10-07 | 2017-08-18 | Cyprumed Gmbh | Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos |
| KR102467968B1 (ko) | 2014-10-08 | 2022-11-16 | 신세틱 바이오로직스, 인코퍼레이티드 | 베타-락타마제 제형 및 이의 용도 |
| US20160122739A1 (en) | 2014-10-31 | 2016-05-05 | Wisconsin Alumni Research Foundation | Factor ix variants and methods of use therefor |
| WO2016088816A1 (ja) | 2014-12-03 | 2016-06-09 | ノーベルファーマ株式会社 | 酢酸亜鉛水和物錠及びその製造方法 |
| CN109890405A (zh) | 2016-08-19 | 2019-06-14 | 布鲁克林免疫治疗有限公司 | Pd-1/pd-l1抑制剂和/或ctla-4抑制剂与含有多种细胞因子组分的生物制剂用于治疗癌症的用途 |
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| SG10201708886RA (en) | 2017-10-30 | 2019-05-30 | Xylonix Ip Holdings Pte Ltd | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER |
| MX2020013883A (es) | 2018-06-22 | 2021-05-27 | Xylonix Ip Holdings Pte Ltd | Tratamientos oncológicos con agentes de zinc. |
-
2016
- 2016-11-01 SG SG10201609131YA patent/SG10201609131YA/en unknown
-
2017
- 2017-10-31 SG SG11201903753QA patent/SG11201903753QA/en unknown
- 2017-10-31 US US16/346,286 patent/US11944640B2/en active Active
- 2017-10-31 AU AU2017354787A patent/AU2017354787B2/en active Active
- 2017-10-31 SG SG10202013112YA patent/SG10202013112YA/en unknown
- 2017-10-31 CA CA3042383A patent/CA3042383A1/en active Pending
- 2017-10-31 JP JP2019545869A patent/JP7083835B2/ja active Active
- 2017-10-31 KR KR1020197015744A patent/KR102616690B1/ko active Active
- 2017-10-31 EP EP17798014.1A patent/EP3534914B1/en active Active
- 2017-10-31 MX MX2019005104A patent/MX395613B/es unknown
- 2017-10-31 WO PCT/SG2017/050545 patent/WO2018084806A1/en not_active Ceased
- 2017-11-01 CN CN201711108631.5A patent/CN108014131B/zh active Active
- 2017-11-01 CN CN202310311382.9A patent/CN116350658A/zh active Pending
-
2019
- 2019-04-30 MX MX2022011372A patent/MX2022011372A/es unknown
-
2022
- 2022-06-01 JP JP2022089345A patent/JP7466822B2/ja active Active
-
2023
- 2023-05-23 AU AU2023203220A patent/AU2023203220B2/en active Active
-
2024
- 2024-04-01 US US18/623,943 patent/US20250025496A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019005104A (es) | 2019-10-30 |
| MX2022011372A (es) | 2022-10-10 |
| EP3534914A1 (en) | 2019-09-11 |
| KR102616690B1 (ko) | 2023-12-21 |
| EP3534914B1 (en) | 2025-07-16 |
| AU2023203220B2 (en) | 2025-07-31 |
| CA3042383A1 (en) | 2018-05-11 |
| CN108014131A (zh) | 2018-05-11 |
| CN108014131B (zh) | 2023-04-14 |
| US11944640B2 (en) | 2024-04-02 |
| CN116350658A (zh) | 2023-06-30 |
| JP7083835B2 (ja) | 2022-06-13 |
| EP3534914C0 (en) | 2025-07-16 |
| WO2018084806A1 (en) | 2018-05-11 |
| SG11201903753QA (en) | 2019-05-30 |
| SG10201609131YA (en) | 2018-06-28 |
| US20250025496A1 (en) | 2025-01-23 |
| US20190255104A1 (en) | 2019-08-22 |
| JP2022116255A (ja) | 2022-08-09 |
| AU2017354787A1 (en) | 2019-05-16 |
| AU2017354787B2 (en) | 2023-02-23 |
| JP2019534330A (ja) | 2019-11-28 |
| AU2023203220A1 (en) | 2023-06-22 |
| JP7466822B2 (ja) | 2024-04-15 |
| KR20190120159A (ko) | 2019-10-23 |
| SG10202013112YA (en) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| PH12017500367A1 (en) | Compounds that inhibit mcl-1 protein | |
| PH12014501560A1 (en) | Carbamate compounds and of making and using same | |
| MX383866B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| IN2015DN00376A (enExample) | ||
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| TW201613578A (en) | Pharmaceutical combinations | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| WO2015035410A8 (en) | Cancer therapy | |
| EA201991069A1 (ru) | Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом | |
| SG10201708886RA (en) | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| MX2020013805A (es) | Derivados de piridopirimidinona para uso como inhibidores de axl. | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага |